By establishing coding and separate payment for certain digital mental health devices, this group from CMS and the FDA hopes to improve access to care.

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication.

The House Health and Human Services committee nearly unanimously approved a bill that would legalize synthetic psilocybin medications for certain conditions, contingent upon approval by the FDA.

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.

Journalist Jacqueline Mendelsohn experienced mood swings and random bouts of crying with her first child. "I remember bursting into tears as I brought my daughter home and walked through the

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum depression.

Pristiq (desvenlafaxine) and Effexor (venlafaxine) are SNRIs. Pristiq treats depression, while Effexor treats depression and anxiety disorders.

Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid valued at around $469M. Read more here.